相关实验视频

Updated: May 9, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

通过准miR-139-5p/HMGB2轴,LINC00534促进了乳腺癌的进展

Qiaomei Liu¹, Wei Xiong²

¹Pain Rehabilitation Department, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, 430060, China.

Discover oncology

|May 2, 2025

概括

这项研究表明,乳腺癌中LINC00534表达升高与患者预后较差有关. LINC00534/miR-139-5p/HMGB2轴代表了乳腺癌治疗的潜在治疗目标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

乳腺癌是女性的主要恶性瘤,需要新的预后和治疗生物标志物.
长非编码RNAs (lncRNAs) 越来越多地与乳腺癌的发展有关.
在乳腺癌中LINC00534的特定作用和机制在很大程度上仍未定义.

研究的目的:

研究LINC00534在乳腺癌进展中的功能作用.
阐明LINC00534的作用背后的分子机制,重点关注其与miR-139-5p的相互作用.
评估LINC00534作为乳腺癌患者潜在的预后生物标志物.

主要方法:

定量实时PCR (qRT-PCR) 用于评估80个患者组织样本中的LINC00534表达.
卡普兰-梅尔分析以将LINC00534水平与患者的存活率和临床结果相关联.
细胞增殖 (CCK-8) 和转移 (Transwell) 测试以评估LINC00534的功能影响.
双露西法酶记者测定证实了涉及LINC00534,miR-139-5p和HMGB2.2的调节轴.

主要成果:

与正常对照组相比,LINC00534在乳腺癌组织和细胞系中显著过度表达 (p < 0.001).
高LINC00534表达与不良预后相关,包括降低生存率和增加复发风险 (Log-rank p = 0.014).
通过miR-139-5p/HMGB2通路,LINC00534显著增强了乳腺癌细胞的增殖,迁移和入侵 (p < 0.001).

结论:

LINC00534显示出作为乳腺癌有价值的预后生物标志物的潜力.
已识别的LINC00534/miR-139-5p/HMGB2分子轴为乳腺癌干预提供了一个有前途的治疗标.

关键词:

乳腺癌乳腺癌乳腺癌我们的 LINC0053434 预测预后预测预测在 miR-139-5p 中使用.

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...